• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

FTC tells court hearing Teva’s patent infringement case against Amneal that Teva patents listed for ProAir HFA should be de-listed

The US Federal Trade Commission (FTC) recently filed an amicus brief in a patent infringement case filed by Teva against Amneal after Amneal submitted an ANDA for a generic version of Teva’s ProAir HFA albuterol MDI in July 2023. In the brief, the FTC contends that the court should grant Amneal’s motion to force device and dose counter patents asserted by Teva to be delisted from the Orange Book, “clearing the way for Americans to access less expensive asthma inhalers.”

In November 2023, the commission issued warning letters to sponsors of NDAs challenging patents listed for numerous inhalers, including more than 40 patents listed for Teva inhalers. Earlier this year, a US Senate committee launched an investigation of inhaler prices and also sent a letter to Teva citing improper listing of patents in the Orange Book as an anticompetitive practice.

According to the brief, “In the FTC’s view, device patents that do not mention any drug in their claims do not meet the statutory criteria for Orange Book listing, and a device patent that is improperly listed in the Orange Book must be delisted.” The brief points out that Teva has listed one of the patents in question (US Patent No. 10,561,808) in relation to 4 APIs, 6 NDAs, and 21 different products, meaning that the patent is clearly not related to a specific drug.

The amicus brief points out that other companies that received warning letters, including GSK, Boehringer Ingelheim, Impax, and AstraZeneca have delisted patents and/or capped out-of-pocket costs for inhalers, while Teva instead defied the commission by re-certifying all 42 of the patents cited by the FTC as improperly listed.

Read the Federal Trade Commission press release.

Share

published on March 28, 2024

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews